α-Synuclein accumulation causes synaptic vesicle trafficking defects and may underlie neurodegenerative disorders:Neurodegenerative disorders,such as Parkinson’s disease(PD)and other synucleinopathies,impact the liv...α-Synuclein accumulation causes synaptic vesicle trafficking defects and may underlie neurodegenerative disorders:Neurodegenerative disorders,such as Parkinson’s disease(PD)and other synucleinopathies,impact the lives of millions of patients and their caregivers.Synucleinopathies include PD,dementia with Lewy Bodies(DLB),multiple system atrophy,and several Alzheimer’s Disease variants.They are clinically characterized by intracellular inclusions called Lewy Bodies,which are rich in atypical aggregates of the protein α-synuclein.While dopaminergic neurons in the substantia nigra are particularly susceptible toα-synuclein-induced aggregation and neurodegeneration,glutamatergic neurons in other brain regions(e.g.cortex)are also frequently affected in PD and other synucleinopathies(Schulz-Schaeffer 2010).展开更多
基金supported by a grant from the National Institutes of Health National Institute of Neurological Disorders and Stroke/National Institute on Aging(NIH NINDS/NIA R01NS078165 to JRM)National Institute of General Medical Sciences(NIH/NIGMS Grant R01GM118933 to EML and RS).
文摘α-Synuclein accumulation causes synaptic vesicle trafficking defects and may underlie neurodegenerative disorders:Neurodegenerative disorders,such as Parkinson’s disease(PD)and other synucleinopathies,impact the lives of millions of patients and their caregivers.Synucleinopathies include PD,dementia with Lewy Bodies(DLB),multiple system atrophy,and several Alzheimer’s Disease variants.They are clinically characterized by intracellular inclusions called Lewy Bodies,which are rich in atypical aggregates of the protein α-synuclein.While dopaminergic neurons in the substantia nigra are particularly susceptible toα-synuclein-induced aggregation and neurodegeneration,glutamatergic neurons in other brain regions(e.g.cortex)are also frequently affected in PD and other synucleinopathies(Schulz-Schaeffer 2010).
